OTC · ETXPF
E-therapeutics Plc
$0.13$0.00 (0.0%)
E-therapeutics Plc: Healthcare · Biotechnology.
Loading market information…
OTC · KDEVF · USD
Stock price, earnings
Quote as of Jun 22, 2022, 02:15 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Karolinska Development AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Karolinska Development AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:49 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.13$0.00 (0.0%)
E-therapeutics Plc: Healthcare · Biotechnology.
$0.84$0.00 (0.0%)
Ecofibre Limited’s quoted price sits in the lower half of its reported 52-week range, 37.96% below the high.
SEK 1.67-SEK 0.04 (-2.22%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.75% below the high.
$4.03+$0.03 (+0.75%)
Biostage, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.22% below the high.
$0.54-$0.00 (-0.37%)
Mindset Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.74% below the high.
$0.82$0.00 (0.0%)
Medivir AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.89% below the high.
$0.03$0.00 (0.0%)
Abliva AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 25.13% below the high.
€1.18-€0.02 (-1.67%)
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
